ASIT biotech announced the publication of a mechanistic study of gp-ASIT+™, its lead product candidate in Phase III for grass pollen allergy, in the Journal of Allergy and Clinical Immunology, the most cited peer-reviewed journal in the field of allergy and clinical immunology. This fifth publication in a prestigious scientific peer-reviewed journal confirms the strength of the gp-ASIT+™ data collected during the initial Phase III trial. The recently published data were obtained in the framework of the first Phase III clinical study (2016-2017) in collaboration with Imperial College London. As planned before the start of the clinical study, the subset of 32 patients recruited at the University Hospital Ghent (Belgium) gave blood samples for the study of the mechanism of action of gp-ASIT+™. The data demonstrate that a short-course treatment (3 weeks) with gp-ASIT+™ is associated with the activation of immune mechanisms that protect patients against grass pollen allergy. This immunologic effect persisted until the end of the pollen season. It is noteworthy that in these patients gp-ASIT+™ induced a reduction of the combined clinical symptom and medication score (CSMS) of -35.1% (p=0.03) during the peak season and -53.7% (p=0.03) during the entire pollen season. These results demonstrate the potency of an adjuvant-free treatment with ASIT+™ peptides and support that gp-ASIT+™ could become an efficient and safe treatment for patients suffering from grass pollen allergy.